United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - escherichia coli - emulsion for injection - inactivated bacterial vaccine - chickens

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - escherichia coli - emulsion for injection - inactivated bacterial vaccine - chickens

Israel - English - Ministry of Health

megapharm ltd - rifaximine - film coated tablets - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria.• non-complicated diverticular diseases.

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - bovine rotavirus, strain uk-compton, serotype g6 p5 (inactivated); bovine coronavirus; escherichia coli, strain o101:k99:f41, fimbrial adhesin f5 and f41, inactivated - emulsion for injection - . - bovine rotavirus + bovine coronavirus + escherichia - cattle - immunological - inactivated vaccine

New Zealand - English - Ministry for Primary Industries

fonterra co-operative group ltd - pseudomonas aeruginosa; proteus vulgaris; streptococcus sp; staphylococcus sp; salmonella sp; escherichia coli (inactivated); propionibacterium acnes; klebsiella pneumonia; shigella dysenteriae; haemophilis influenzae - pseudomonas aeruginosa 0 vaccine; proteus vulgaris 0 vaccine; streptococcus sp 0 vaccine; staphylococcus sp 0 vaccine; salmonella sp 0 vaccine; escherichia coli (inactivated) 0 vaccine; propionibacterium acnes 0 vaccine; klebsiella pneumonia 0 vaccine; shigella dysenteriae 0 vaccine; haemophilis influenzae 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

hipra new zealand limited - staphylococcus aureus cp8 (inactivated); escherichia coli j5 (inactivated) - staphylococcus aureus cp8 (inactivated) 0 vaccine; escherichia coli j5 (inactivated) 0 vaccine - vaccine

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila, or mycoplasma pneumoniae [see dosage and administration (2.1) and clinical studies (14.2)] . mdrsp isolates are isolates res

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals ,inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible staphylococcus   aureus , pseudomonas   aeruginosa , serratia   marcescens , escherichia   coli , klebsiella   pneumoniae , haemophilus   influenzae , or streptococcus   pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas   aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see   clinical   studies   ( 14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus   aureus , streptococcus   pneumoniae (including multi-drug-resistant streptococcus   pneumoniae [mdrsp]), haemophilus   influenzae , haemophilus   parain

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see   clinical   studies   ( 14.1)] . levofloxacin is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila, or mycoplasma pneumoniae [see   dosage   and   administration   ( 2.1)   and   clinical   studies   ( 14.2)] . mdr

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible staphylococcus   aureus , pseudomonas   aeruginosa , serratia   marcescens , escherichia   coli , klebsiella   pneumoniae , haemophilus   influenzae , or streptococcus   pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas   aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see   clinical   studies   ( 14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus   aureus , streptococcus   pneumoniae (including multi-drug-resistant streptococcus   pneumoniae [mdrsp]), haemophilus   influenzae , haemophilus   parain